Ertugliflozin L-pyroglutamic acid

Ertugliflozin L-pyroglutamic acid (CAS No.: 1210344-83-4) is a small molecule synthetic research compound in the gliflozin class that is primarily categorized as a selective inhibitor of the sodium dependent glucose cotransporter 2 system, with established activity against human SGLT2 and a reported inhibitory potency in the sub nanomolar range, placing its functional in vitro activity in the nanomolar to low micromolar concentration domain depending on assay configuration and cellular context; mechanistically, this agent is used to interrogate renal glucose reabsorption biology by reducing SGLT2 mediated glucose transport, thereby supporting pathway level studies of glucose handling, metabolic adaptation, and transporter selective pharmacology in biomedical research frameworks, while its L-pyroglutamic acid form is commonly treated as a defined investigational material for structure activity and target engagement studies; in drug discovery settings, it is typically applied in transporter inhibition assays, selectivity profiling against related transport systems, and comparative benchmarking in cell based models expressing human SGLT2, and it may also be incorporated into animal model studies of dysregulated glucose metabolism to examine pharmacodynamic relationships and translational hypotheses under controlled preclinical conditions, where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.